Skip to main content

Advertisement

Table 1 Baseline demographics and disease status in 147 patients with axial spondyloarthritis receiving either standard (NSAID and/or physiotherapy) or TNFα inhibitor therapy

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

  Standard therapy (n= 68) TNFα inhibitor (n= 79)
Age 40.44 (12.86) 40.29 (10.70)
Males No (%) 47 (69%) 64 (81%)
Symptom duration 16.12 (10.62) 16.94 (9.64)
BASDAI 3.71 (2.24) 5.99 (2.12)
Total back pain 3.69 (2.67) 5.75 (2.57)
Nocturnal back pain 4.03 (2.75) 6.05 (2.60)
Patient global score 3.85 (2.57) 5.91 (2.84)
BASFI 2.36 (2.56) 4.83 (2.71)
HLA B27a 55 (87%) 58 (85%)
C-reactive protein 6.83 (9.53) 18.37 (18.84)
ASDAS 2.29 (1.02) 3.55 (1.10)
mSASSS 12.32 (18.15) 17.47 (19.08)
  1. ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index [15]; BASFI, Bath Ankylosing Spondylitis Functional Index [13]; HLA, human leukocyte antigen; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score [14]; NSAID, nonsteroidal anti-inflammatory drug; TNFα, tumor necrosis factor alpha. Values represent mean (standard deviation) or number (percentage). aMissing values in 5 and 11 patients of the standard therapy and TNFα inhibitor groups, respectively.